The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases.

Miedany Y, El; S, Youssef; I, Ahmed; Gaafary M, El

doi:10.1111/j.1572-0241.2006.00384.x

Public

The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases.

Shared by NobleBlocks on Feb 1, 2006 • 12:00 AM UTC

Authors:

El Miedany Y

Youssef S

Ahmed I

Abstract

Background While traditional nonsteroidal antiinflammatory drugs (t-NSAIDs) are relatively contraindicated in patients with inflammatory bowel disease (IBD) for fear of disease aggravation, controlled clinical trials showed that cyclo-oxygenase-2 inhibitors have fewer gastrointestinal side effects t...

Discussions